Register now

Program

PROUDLY SPONSORED BY

Platinum Sponsor

Gold Sponsor

Silver Sponsor

Industry Partner

PROGRAM AT A GLANCE >>

CONFIRMED SPEAKERS AND FULL AGENDA

PTA-C/26 From Innovation to Implementation — Shaping Tomorrow’s Standards of Care Today

Australia’s premier technology in diagnostics congress returns for 2026 — with a focus on delivering flexible, personalised, and preventative healthcare. 

Australia’s healthcare system is under mounting pressure from an ageing population, increased chronic disease, and workforce challenges. Our important infrastructure under Medicare and State Health systems urgently need to evolve to meet these challenges using scalable, technology-enabled models of care. 

PTA-C/26 is moving the conversation forward from ideas to action: 

  • Predict. Prevent. Personalise – How innovative diagnostics enable earlier detection, targeted prevention, and tailored care. An efficient and sustainable approach driving better outcomes for patients and systems alike. 
  • Innovation in Motion – What it takes to deliver the right test to the right patient at the right time — in real-world, flexible high-volume, and decentralised settings. 
  • The Value Fountain – Why the ‘value of knowing’ and other fundamental values must be central to healthcare decision-making. Exploring diagnostics as a cornerstone of value-based care. 

Expect real-world case studies, diverse voices across the health continuum, health economic arguments, government perspectives, and hands-on workshops designed to spark practical change. 

Who Should Attend? 
This congress is designed to unite healthcare professionals across disciplines. Topical and action-oriented content ideal if you work in:

  • Pathology or pathology services
  • General Practice or other healthcare settings
  • Pharmacy
  • Health policy
  • Medical technology industry
  • Government health services
  • Medical and health research

Adopting a drill down format - plenary lecture to set the scene, panel discussion to spotlight experts in the field, real-world case studies with technology showcases, and breakout workshops encouraging delegates to add their expertise – the congress will result in recommendations to drive the policy and infrastructure of our healthcare system towards much-needed evolution to improve healthcare delivery. 

We invite you to participate in this congress and discussion forum. Together we can focus on meaningful change to drive Australia’s health system forwards. This isn’t just another conference, it’s a mission to get the right test in front of the right patient at the right time. 

CONFIRMED SPEAKERS AND FULL AGENDA

Value Fountain: “how do we measure (and value) what really matters”

Chair:

Dr Geoff Lester, Vascular Medicine and Perioperative Physician

Geoff is a physician, researcher, patient advocate and health economist passionate about platforming and prioritising patient experience within health system processes and policy. Geoff combines his medical training and studies on economic impacts of health conditions with his own extensive personal experience navigating health and hospital systems.

Featured technology showcases

Towards Predictive Genomics: Key Learnings for Australia

Alberto Domingo Bayarri – Spain, Global Strategic Partnerships and Policy, Thermo Fisher Scientific

Alberto Domingo heads Thermo Fisher Scientific’s strategy for Global Partnerships and Policy in Microarray Genotyping, focusing on the expansion of predictive genomics. With a background in public affairs, he has worked for a decade in different policy positions including in public institutions, patient advocacy, think tanks and government affairs consulting, specializing in health and research policy. Alberto’s work focuses on connecting stakeholder perspectives to advocate for positive policy change, with the aim of incorporating innovations in health care systems.

ABSTRACT: Advances in genomic technologies are reshaping healthcare by enabling a shift from reactive treatment to personalised prevention. This presentation will explore how genomic information—particularly polygenic risk derived from genome-wide association studies—can be integrated with traditional risk factors to better predict disease susceptibility and guide early intervention strategies. In addition, pharmacogenomics offers the ability to anticipate individual responses to therapies, supporting more precise and effective treatment decisions. Cost-effective, high-throughput technologies such as microarray genotyping now make population-scale risk profiling increasingly feasible.

Drawing on international experience, the session will highlight leading predictive genomics initiatives, including large-scale biobanking and cohort programs such as the Taiwan Precision Medicine Initiative and the Million Veterans Program. These examples demonstrate how genomic insights are being translated into preventative health strategies at scale.

Despite these advances, significant challenges remain in embedding predictive genomics into routine practice. While the technology is mature and evidence of utility is growing—particularly in areas such as cardiovascular disease and cancer—key gaps persist in cost-effectiveness data, equitable representation across diverse populations, and, most critically, enabling health policy frameworks. Integration with electronic health records, development of clinical protocols, and establishment of standardised testing and reporting pathways are essential next steps.

The presentation will conclude with recommendations for Australia to accelerate the adoption of predictive genomics. These include implementing risk-based screening programs, integrating genomic data into healthcare systems, expanding pre-emptive pharmacogenomic testing, and fostering national coordination across stakeholders. Harnessing predictive genomics offers a significant opportunity to enhance disease prevention and deliver more sustainable, personalised healthcare.

Towards Predictive Genomics: Key Learnings for Australia

A/Prof Jun Yang, MBBS FRACP PhD
Head, Endocrine Hypertension Group, Hudson Institute of Medical Research
Chief Investigator, Primary Aldosteronism Centre of Research Excellence (PACE)
Senior Research Fellow, Department of Medicine, Monash University
Consultant Endocrinologist, Monash Health

A/Professor Jun Yang is the Head of the Endocrine Hypertension Group at Hudson Institute of Medical Research, a Consultant Endocrinologist at Monash Health, and a Senior Researcher in the Department of Medicine at Monash University, Victoria, Australia. Jun graduated from Monash University with a MBBS (Hon) in 2001, attained her FRACP in 2010, and completed a PhD in 2013 focusing on tissue-selective coregulators of the mineralocorticoid receptor (MR). She has since advanced basic and clinical research in the field of MR-driven cardiovascular disease, particularly primary aldosteronism, contributing to 133 original publications. She established Victoria’s first Endocrine Hypertension Service, co-leads the Primary Aldosteronism Centre of Excellence, and enjoys fostering national and international collaborations to enhance the detection and management of primary aldosteronism for better patient outcomes.

Abstract: Hypertension is a significant healthcare burden being the key risk factor for the development of Cardiovascular disease. Primary Aldosteronism is a secondary cause of hypertension where individuals have a much higher risk of cardiovascular events. One in ten individuals with hypertension have PA. Specific treatments and cures are available when cases are identified lowering downstream risks such as cardiovascular disease and metabolic complications—all major drivers of long term healthcare expenditure.

The session will aim to explore both health economics and personal lived experience and the value of having a diagnosis versus living without one. The talk will examine how the diagnostics provides clarity and personalising therapeutic pathways and impacts on clinical outcomes that reduces both systemic and personal healthcare costs. Professor Yang brings a very unique and personal side to this topic as both of her parents have been diagnosed with Primary Aldosteronism.

Theme Overview

Australia’s health system continues to measure what’s easiest, often ignoring what matters most. We chase activity, volume, and cost reduction, but rarely measure the “value of knowing”: the clinical, economic, and human consequences of access to timely, accurate diagnostics. What’s more, we rarely address the far greater cost of not knowing.

The Value Fountain challenges us to rethink how value is defined, measured, and rewarded across the health system. It places diagnostics at the centre of value-based care, exploring how insight, instead of intervention, drives better outcomes for patients, health systems, and the economy.

This conversation goes beyond efficiency. It asks how we quantify the human, societal, and productivity benefits of innovation, and how Australia can evolve funding and policy models that recognise health as an investment, not an expense.

Intended Discussion Focus

  • The Value of Knowing: Why knowledge in the form of early, accurate, actionable information, is the most undervalued currency in healthcare.
  • The Cost of Not Knowing: Real-world examples where diagnostic delay or underuse leads to higher system costs, poorer patient outcomes, and lost productivity.
  • Cost vs Outcome: How chasing the lowest unit cost distorts investment and concentrates access in large population centres, leaving equity and prevention behind.
  • Quantifiable vs Human Impact: Balancing measurable system efficiencies with human and societal benefit drawing on stories that make “value” tangible.
  • Activity vs Outcome: Moving from throughput metrics to patient-centred outcomes, and exploring funding frameworks that reward smarter testing, not more testing.
  • The Value of Innovation: How new diagnostics and digital tools generate economic and productivity gains, and why policy must evolve to capture and reinvest that value.

Key Takeaways for Delegates

Insight: Understand why diagnostics must sit at the heart of value-based healthcare frameworks.

Evidence: Explore both quantifiable and human measures of value including health outcomes, avoided cost, and lived impact.

Action: Identify strategies to reframe health investment narratives for policymakers, funders, and investors.

KEYNOTE SPEAKERS

Harry Iles-Mann, Digital Health Expert, Consumer Representative Advisor Department of Health

An experienced disability advocate, collaborative design and lived-experience engagement consultant, mental health ambassador, speaker, and health strategist. Pairing lived-experience and health sector expertise with a collaborative design approach to practicing partnerships, Harry supports organisations and people to translate lived-experience contributions into innovative, equitable, and impactful change in health care.

Juliana Iles-Mann, Program Director, Statewide Laboratory Information Systems, NSW Health Pathology

With extensive experience as a leader in the public health system, Juliana works to strengthen connectivity across healthcare providers to ensure pathology is embedded as an integral clinical service. Juliana has also navigated her son, Harry’s long-term engagement with the health system and will speak to her experience both as a healthcare professional and a mother.

PANEL SPEAKERS

“how do we measure (and value) what really matters?”

Daniel McCabe, First Assistant Secretary Medicare Benefits and Digital Health, DHDA

Daniel is responsible for providing policy advice on the Medicare Benefits Scheme to deliver access to medical and health services for all Australians. Daniel also has policy responsibility for digital health to connect consumers and health care providers with their health information across Australia’s health system. Daniel is a Board member of the Australian Digital Health

Prof Erwin Loh, President of the Royal Australasian College of Medical Administrators

Professor Erwin Loh is the current President of the Royal Australasian College of Medical Administrators, the specialty medical college for medical leaders, and Director of Medical Services at Peninsula Private Hospital. A recognised leader in health ethics, Prof Loh is a member of the Australian Health Ethics Committee (AHEC) of the NHMRC, and a member of the AHEC AI Working Group, holds adjunct professorships at University of Melbourne, Macquarie University and Monash University and is a member of the Association of Professional Futurists

A/Prof Bonny Parkinson, Associate Professor in Health Economics at Macquarie University

Interim Deputy Director at the Macquarie University Centre for the Health Economy, A/Prof Parkinson’s expertise is in the field of health economics, especially regarding pharmaceutical policy, economic evaluation methodology, cancer, hearing, and precision medicine. She currently co-leads the health technology assessment stream, and has been involved in over 70 evaluations of submissions to PBAC, MSAC and NDSS since 2009.

Emily Casey, Founder & Director, What the Health & Community & Partnerships Lead, Tenmile

Having started What the Health as a media company platforming health innovation news, Emily has since built an engaged readership and community over 10,000 strong – providing discussion, networking, and learning forums for health startups and big organisations alike. Her passion for adding value to the health innovation space is echoed in her role at TenMile, a health technology investment fund that partners with early-stage companies to target unmet needs in healthcare and develop the Australian health commercialisation ecosystem.

Innovation In Motion: “Universal vs Uniform healthcare – supporting a diverse population with a diversity of solutions”

Chair:

Dr Robert Grenfell, Chair West Vic Primary Health Network

Rob has specialist expertise in health system analysis, strategic planning, governance, health risk management, and equity-focused care. He is passionate about access to healthcare in rural communities and bringing innovative systems to improve equity in regional settings.

Featured technology showcase

Topic: Lighting the Way: How POC Haemolysis Detection Impacts Clinical Decision Making and Patient Outcomes

Speaker: TBC

Overview: Haemolysis, the #1 source of preanalytical error, while prevalent throughout the hospital, is often unrecognised. This can negatively impact potassium (K+) results and patient care. Haemolysis occurs when the red blood cell membrane ruptures, causing Potassium (K+) to leak into the surrounding fluid. This leads to an elevation in K+ results. Haemolysis detection has not been available for whole blood potassium testing, causing inappropriate patient management, inefficient utilisation of staff/nursing time, negative impacts on patient satisfaction, and increased costs to the healthcare system. Unsuitable and/or delayed treatment pathways and longer length of stay underpin the impact of not having the early detection technology to predict, prevent, and personalise the required treatment for each patient entering the triage process. In this talk, we will explore how point-of-care Haemolysis Detection can positively impact patient outcomes through effective, informed and preventative clinical decision making.

Werfen’s GEM® Premier™ 7000 blood gas analyzer with iQM®3 offers the first automated, point-of-care (POC) whole-blood haemolysis detection, flagging haemolysed samples in 45 seconds. Using advanced IntraSpect™ technology, it provides real-time, preanalytical error detection (haemolysis, clots, bubbles) to improve accuracy of potassium results. A breakthrough in blood gas testing.

Theme Overview

The future of healthcare will depend on how effectively we can deliver the right test, to the right patient, at the right time. While central laboratories have a stronghold as the engine room of quality at scale, innovation now enables diagnostics to move closer to the patient: into clinics, communities, and even homes.

This session explores how technology can transform the patient journey. Can we create continuity across the system and meet people where they are? From point-of-care testing (POCT) and self-collection models to wearable diagnostics and consumer-driven health, innovation in motion is about re-engineering how, where, and by whom care is delivered.

Intended Discussion Focus

  • Evolving the System: How decentralised models complement central labs by extending reach, improving timeliness, and reducing system bottlenecks.
  • Continuity of Care: Meeting people where they are. Whether that be in rural and remote settings, primary care, or community-led programs. How can we ensure diagnostic access aligns with lived realities?
  • Technology as an Enabler: How portable, digital, and connected diagnostics provide the lever for transition to a more flexible, responsive, and equitable healthcare system.
  • Systemic Change: What structural and policy shifts are required to make these new models sustainable, safe, and integrated into mainstream care?
  • Consumer-Driven Health: Exploring blurred lines between medical and lifestyle technologies including wearables, home monitoring, self-testing, and the implications for regulation, trust, and data.

Key Takeaways for Delegates

Clarity: Understand how decentralised diagnostics complement, rather than compete with, centralised systems.

Evidence: See real-world examples of innovation improving access and outcomes, particularly for underserved populations.

Action: Identify the policy, funding, and infrastructure enablers that will allow innovation to move from pilot to practice.

KEYNOTE SPEAKER

Adj/Prof Anita Ghose, Chair Australian Information Industry Association, Health Policy Advisory Board

A global & national thought leader on the future of health and digitisation of care, Adj/Prof Ghose has a strong focus on well-being outcome, interoperability, and human-centered design. Her extensive advisory and taskforce experience has driven technology-enabled solutions across aged care, women’s health, and digital health.

PANEL SPEAKERS

“Universal vs Uniform healthcare – supporting a diverse population with a diversity of solutions”

Dr Michael Wright, President of the Royal Australian College of General Practitioners

A general practitioner (GP), health economist and health services researcher, Michael combines clinical practice with strategic appointments and academic research analysing the effects of health policy on the quality and performance of primary care. In addition to leading RACGP, Michael is Associate Professor at the UNSW International Centre for Future Health Systems and maintains his clinical practice

Dr Michael Page, CEO Clinipath Pathology

In addition to leading the SONIC laboratory in Western Australia, Michael is a senior lecturer at the UWA medical school and an examiner for the Royal College of Pathologists of Australasia A chemical pathologist, Michael has an active clinical interest in lipid disorders, including familial hypercholesterolaemia). With a keen interest in the health of doctors, patients and the community, Michael is a former President of the Australian Medical Association (WA) and is passionate about elevating ways for pathology to add value to improve patient experience and empowerment.

Zoë Milgrom, Co-founder and Chief Clinical Officer, Eugene

A certified Genetic counsellor, Zoë spent over a decade working within the public and private health systems, before founding Eugene with a goal to increase genetic awareness and provide guidance and support, and testing that is relevant and ethical. Zoë is passionate about developing a new client centred model of healthcare that empowers individuals to make proactive and informed healthcare choices.

Dr Elizabeth Deveny, CEO Consumer Health Forum

Working at the intersection of policy, technology and lived experience, Elizabeth has a focus on how people actually access and use care. She has led major health system reforms across digital health and primary care, and is known for bringing a clear consumer lens to complex decisions about funding, pricing and design. Elizabeth is particularly interested in how innovation, including diagnostics and at-home testing, can improve access, without widening gaps in care.

Bob Partridge, Regional Laboratory Operations Manager, Pathology Queensland

Bob has extensive experience in the Management and Leadership of rural and remote Pathology Services and integration of rural and remote labs into a statewide coordinated service. Leading and managing the operations of the 22 Regional laboratories across Queensland, a land mass approximately eight times the size of Victoria and seven times the size of the UK. Bob is focussed on innovative and cost-effective patient focused solutions to bring timely and equitable health services, with a particular interest in improving the leadership competency for enabling change as a strategic capability to increase change capacity and responsiveness in organisations.

Predict. Prevent. Personalise

Chair:

Matthew Britland, Co-founder and Director, Edge Medical Solutions

Experienced Medical Affairs Director with a demonstrated history of working in the pharmaceuticals industry and clinical roles. Skilled in Pharmaceutical Medicine, Oncology and Haematology . Strong professional with a MMedSc focused in Pharmaceutical Medicine from UNSW Australia. Currently working towards DrPH which focuses on the role of Medical Affairs in the Quality use of Medicine (QUM) and its impact on patient outcomes.

Theme Overview

Australia’s healthcare system is reaching a breaking point—costs are escalating, chronic disease is increasing, and system inefficiencies are eroding sustainability. While incremental funding boosts have offered temporary relief, they have largely “kicked the can down the road.” What’s needed is genuine system change. Can we shift from reactive, sickness-based care to proactive, patient-centred health built on prediction, prevention, and personalization? PTA-C/26 invites speakers to explore how innovative diagnostics and enabling technologies (such as genomics, proteomics, point-of-care testing, AI and digital health) can underpin this transformation.

This session asks: What would it take for Australia to truly value prevention as an investment, not a cost?

Intended Discussion Focus

  • Big Picture Health Challenges: Draw on experience and insights to frame Australia’s current health trajectory of rising chronic disease burden, workforce pressures, and widening inequities.
  • System Sustainability: Why the current model is no longer fit for purpose, and the role pathology technology plays to help rebalance the system toward proactive health.
  • Investment Mindset: Reframe healthcare as an economic enabler rather than a cost centre. Illustrate both the economic and personal stories. Paint the picture of how earlier diagnosis and targeted prevention deliver measurable returns to individuals, communities, and governments.
  • Global Perspectives: Denmark and other high-performing systems have redirected investment toward primary and preventative care (e.g., 30% of health spend vs Australia’s 7.5%) with demonstrable innovation and improved outcomes. What can we learn from them?
  • Technology as a Framework Enabler: Highlight how diagnostic and digital innovation fits into a prevention-first approach. Address the policy and funding gaps that currently undervalue and underutilise proven technology.
  • Next-Generation Expectations: Explore how digital natives view and access healthcare. The trends towards demanding immediacy, transparency, and personalization. What does that mean for system design to be agile and adaptive to the fast pace of technology evolution?

Key Takeaways for Delegates

Clarity: Understand why Australia’s current trajectory is unsustainable and how prevention-driven investment can reverse it.

Evidence: Learn from international and domestic examples that quantify the benefits of proactive healthcare.

Action: Identify concrete policy, funding, and regulatory levers to accelerate adoption of predictive and preventative diagnostics.

KEYNOTE SPEAKER

Hans Erik Henriksen, Vice President for QUMEA, Denmark

Senior healthcare and health-technology leader with more than 30 years’ experience driving system-level change through digital innovation. As former CEO of Healthcare DENMARK, he played a central role in promoting and scaling Danish healthcare solutions internationally, supporting a national strategy that prioritised prevention, digital health, and home-based care. Across executive roles spanning primary care, hospitals, home-based chronic care and national public–private partnerships, Hans Erik brings practical insights into how technology, policy and investment can combine to deliver better outcomes for patients, clinicians and health systems.

PANEL SPEAKERS

“from ideas to action – where is it done well, what can we learn, and how do we scale?” 

Tiffany Boughtwood, Australian Health Genomics Commissioner, leading Genomics Australia

Providing advice to Government based on broad engagement with the genomics sector and community. Tiffany has 30 years’ experience in molecular biology and management: leading academic and diagnostic genomic programs; collaborating internationally in genomic research; and consulting in health genomic implementation.

Dr Kean- Seng Lim, General Practitioner, Medical Advisor, Co-Founder and Innovator

Across 30+ years as a GP, Dr Lim has found innovative ways to meet evolving healthcare challenges and patient needs. Passionate about connecting information to meaningful outcomes Dr Lim is Chief Medical Advisor for health informatics company Pen CS, and co-founder of CareMonitor - allowing healthcare teams to deliver high-quality care where and when it’s needed.

Dr Steven Lu, General Practitioner, Co-founder & Chief Medical Officer of Everlab

With over 15 years of clinical experience spanning intensive care, cardiothoracic surgery, and general practice, Steven has built his career around a simple conviction: healthcare should prevent disease, not just respond to it. Through longitudinal data, advanced diagnostics, and doctor-led interpretation, Steven and his team are building the infrastructure for proactive care that anticipates health risks years before symptoms emerge.

Vanessa (Ness) Tyrrell, ZERO Childhood Cancer Program Director, Children’s Cancer Institute

Immediate Past President of the Human Genetics Society of Australasia (HGSA), Member of the NSW Health Genomics Strategy Translational Medicine Committee, among other positions, Ness has actively contributed to state and federal governments’ and professional bodies’ advisory committees, review, consultation, and development of policy, and the implementation of genomics and precision medicine in Australia.

Bridget Totterman, CEO Pharmaceuticals Society Australia

A registered pharmacist, director, business owner and established leader. Bridget is passionate about health care and the role we all play in optimising health outcomes. Drawing on a career spanning entrance level roles to the C-suite, Bridget brings an “all of business” skill set with excellent knowledge of financials, human resource management, risk management, relevant laws including health legislation, clinical governance and operations.

INNOVATORS SHOWCASE

AusBiotech, as commercial partners of the Innovators Forum, are sponsoring FIVE promising IVD innovators to present (10 minutes) to an expert panel and 150+ delegates including policy makers, payers, patient groups, pathology providers and the healthcare professionals that care for Australian patients.

This focused session is dedicated to showcasing the opportunities available to our healthcare system, highlighting the structural and environmental barriers limiting commercialisation and adoption, while providing targeted, actionable feedback to accelerate your commercialisation journey.

In addition to full delegate access to all sessions, workshops, and networking events across the two-day forum, the five successful innovators will gain:

Strategic advice from people who’ve successfully commercialised in this market

Access to the decision-makers who could adopt, distribute, or acquire your technology Validation from respected industry voices that your solution matters

Real-world insights into barriers you haven’t anticipated yet

Connections to experts and influencers that could accelerate your path to market

 

The Panel Includes:

Senior Diagnostics Industry Rep – knows every pitfall and shortcut of Australian market

Pathology Service Provider – insights on what matters to labs considering adoption

Venture Capital Rep – can assess investment readiness and commercial viability

Proven Commercialization Expert – broadscale expertise on market access barriers

 

Is your innovation ready to change the future of healthcare?

Applications are welcome from innovators and SMEs with high potential IVD technology that address an unmet medical need or significantly improve current practice.

You’re a good fit if:

✓ You have an IVD technology at TRL 7 or above

✓ You’re pre-revenue or early-stage commercial

✓ Your technology addresses an unmet medical need or improves current practice

✓ You’re ready to demonstrate the health impact of your tech

✓ You can articulate your value proposition clearly in 10 minutes

✓ You’re serious about commercializing in Australia

The Forum format includes a 10-minute presentation on the new technology, followed by a 5-minute discussion with a panel of experts and may include live delegate polling and/or questions from the audience.

 

How to Apply

Applications close April 30th , 2026.

VIP FIRESIDE CHAT

Dr. Patricia M. Davidson RN PhD Co-Director of the International Centre for Future Health Systems

Dr. Patricia Davidson is a Vice Chancellor’s Distinguished Fellow at the University of New South Wales Sydney. She previously served as Vice Chancellor and President of the University of Wollongong and is currently the Co-Director of the International Centre for Future Health Systems. Her previous academic leadership positions include Dean of the Johns Hopkins School of Nursing. Current leadership roles, include Chair of the NSW International Education Advisory Board, Chair of Her Heart and membership on the Research Australia board.

Harry Iles-Mann, Digital Health Expert, Consumer Representative Advisor Department of Health

An experienced disability advocate, collaborative design and lived-experience engagement consultant, mental health ambassador, speaker, and health strategist. Pairing lived-experience and health sector expertise with a collaborative design approach to practicing partnerships, Harry supports organisations and people to translate lived-experience contributions into innovative, equitable, and impactful change in health care.

Hans Erik Henriksen, Vice President for QUMEA, Denmark

Senior healthcare and health-technology leader with more than 30 years’ experience driving system-level change through digital innovation. As former CEO of Healthcare DENMARK, he played a central role in promoting and scaling Danish healthcare solutions internationally, supporting a national strategy that prioritised prevention, digital health, and home-based care. Across executive roles spanning primary care, hospitals, home-based chronic care and national public–private partnerships, Hans Erik brings practical insights into how technology, policy and investment can combine to deliver better outcomes for patients, clinicians and health systems.

OPTIONAL SPONSORED SESSIONS

BREAKFAST SESSION WEDNESDAY 27th 7:50 – 8:45 – DRAWING ROOM 2

TBD

LUNCH SESSION WEDNESDAY 27th 12:45-13:35 – BALLROOM

Speaker: TBD
Overview
TBD

LUNCH SESSION THURSDAY 28th 12:30-13:25 – TBD

The Value of Knowing: How Digital Health Enables Better Decisions

Speaker: Cassandra Solari, Head of Digital Health and Integrated Solutions. Roche Diagnostics Australia

Overview

The transition to proactive, personalised care isn't just a trend—it has become a systemic necessity.   

For decades, diagnostics have been the silent backbone of medicine, yet the system remains largely reactive. The traditional model—centralised, reactive, and siloed—is no longer viable in an era defined by fiscal pressure and the demand for value-based care.  Predictive and personalised care is no longer a luxury; it is the new benchmark for operational efficiency and market relevance. 

To bridge the gap between data and delivery, the industry must evolve from being a mere supplier to becoming a core architectural partner in digital health.  

PROGRAM AT A GLANCE (updated as planning progresses)

WEDNESDAY 27th MAY
7:50-8:45 Industry-Sponsored Breakfast Roundtable
8:50-9:25 Welcome to Country and Opening Ceremony
With Remarks from VIP Speaker
9:25-10:10 Opening Keynote (P1)
The Value Fountain: Diagnostics informing patient journey
10:10-10:40 Morning Tea
10:40-11:55 Panel Discussion (D1)
How do we measure (and value) what really matters?
12:00-12:45 Case Study & Technology Showcase (C1)
12:50-13:45 Lunch (optional Industry Showcase)
13:45-14:30 Concurrent Workshop 1
Real World Evidence – what is the true value of knowing?		 Concurrent Workshop 2
Measuring what matters – impacts on decision making		 Concurrent Workshop 3
What does fit-for-purpose policy look like?
14:35-15:20 Plenary (P2)
Innovation in Motion: Meeting people where they are
15:20-15:45 Afternoon Tea
15:45-17:00 Panel Discussion (D2)
Universal vs Uniform healthcare – supporting diverse populations with a diversity of solutions
17:00-18:30 Networking Drinks
THURSDAY 28th MAY
7:50-8:45 Industry-Sponsored Breakfast Roundtable
8:50-9:35 Case Study & Technology Showcase (C2)
9:35-10:20 Concurrent Workshop 4
How to scale from pilot to mainstream 		Concurrent Workshop 5
Scope of practice – driving value at every touchpoint 		Concurrent Workshop 6
How do we get the right test to the right patient at the right time?
10:20-10:45 Morning Tea
10:45-11:30 Plenary (P3)
Predict. Prevent. Personalise: Re-imagining healthcare from reactive to proactive Hans Erik Henriksen (Denmark)
11:30-12:45 Panel Discussion (D3)
From idea to action – where is it done well, what can we learn, and how do we scale?
12:45-13:35 Lunch (optional Industry Showcase)
13:35-14:20 Case Study & Technology Showcase (C3)
13:35-14:20 Concurrent Workshop 7
Learning from best practice 		Concurrent Workshop 8
Wellness vs Healthcare – when to start the diagnostic journey 		Concurrent Workshop 9
Critical success factors – what does good look like?
14:05-15:20 Innovator Showcase and Horizon Scan
15:20-15:45 Afternoon Tea
15:45-16:30 Fireside Chat with VIPs and Closing Remarks
Conference Program
WEDNESDAY 27th MAY
7:50–8:45 TBD Breakfast RoundtableDRAWING ROOM 2
8:50–9:25 Welcome to Country and Opening Ceremony With Remarks from Hon Mark Butler, MP and Dr Michael Bonning BALLROOM
9:25–10:10 Opening Keynote (P1) Harry & Juliana Iles-Mann The Value Fountain: Diagnostics informing patient journey BALLROOM
10:10–10:40 Morning Tea
10:40–11:55 Panel Discussion (D1) Daniel McCabe, Prof Erwin Loh, A/Prof Bonny Parkinson, Emily Casey, Harry Iles-Mann How do we measure (and value) what really matters? BALLROOM
12:00–12:20 Thermo Fisher Scientific Case Study (C1a) TBD BALLROOM
12:25–12:45 DiaSorin Case Study & Technology Showcase (C1b) Prof Jun Yang BALLROOM
12:45–13:35 Lunch (optional Cepheid Industry Showcase) – Industry‑Sponsored Lunch Symposium
13:35–14:20 Concurrent Workshop 1 Deidre Mackechnie Real World Evidence – what is the true value of knowing? DRAWING ROOM 1 Concurrent Workshop 2 Colman Taylor Measuring what matters – impacts on decision making BALLROOM Concurrent Workshop 3 Joshu O Aderinto What does fit-for-purpose policy look like? DRAWING ROOM 2&3
14:20–14:30 Workshop reflections BALLROOM
14:30–14:40 Innovation in Motion Session Introduction
14:40–15:20 Werfen Case Study & Technology Showcase (C2) BALLROOM
15:20–15:45 Afternoon Tea
15:45–17:00 Panel Discussion (D2) Dr Michael Wright, Dr Michael Page, Zoë Milgrom, Bob Partridge, Dr Elizabeth Deveny Universal vs Uniform healthcare – supporting diverse populations with a diversity of solutions BALLROOM
17:00–18:30 Networking Drinks DRAWING ROOMS
THURSDAY 28th MAY
8:00–8:40 Plenary (P2) Adj/Prof Anita Ghose Innovation in Motion: Meeting people where they are BALLROOM
8:40–9:25 Concurrent Workshop 4 Dr Rob Grenfell How to scale from pilot to mainstream DRAWING ROOM 2 Concurrent Workshop 5 Madeline O'Donoghue Scope of practice – driving value at every touchpoint DRAWING ROOM 1 Concurrent Workshop 6 Dean Whiting How do we get the right test to the right patient at the right time? BALLROOM
9:25–9:35 Workshop reflections BALLROOM
9:35–10:10 Plenary (P3) Hans Erik Henriksen (Denmark) Predict. Prevent. Personalise: Re-imagining healthcare from reactive to proactive BALLROOM
10:10–10:30 Morning Tea
10:30–11:45 Panel Discussion (D3) Tiff Boughtwood, Dr Stephen Lu, Ness Tyrell, Dr Kean-Seng Lim, Bridget Totterman From idea to action – where is it done well, what can we learn, and how do we scale? BALLROOM
11:50–12:30 Illumina Case Study & Technology Showcase (C3)
12:30–13:25 Lunch (optional Roche Industry Showcase)
13:25–14:15 Concurrent Workshop 7 Katie Elis Learning from best practice DRAWING ROOM 2&3 Concurrent Workshop 8 Prof Charlotte Hespe Wellness vs Healthcare – when to start the diagnostic journey BALLROOM Concurrent Workshop 9 TBD Critical success factors – what does good look like? DRAWING ROOM 1
14:15–14:25 Workshop reflections
14:25–14:45 Afternoon Tea
14:45–16:00 Innovator Showcase and Horizon Scan sponsored by AusBiotech BALLROOM
16:00–16:30 Fireside Chat with and Closing Remarks Prof Patricia Davidson, Hans Erik Henrikson, Harry Iles-Mann BALLROOM

INVITED SPEAKERS

Justin Meredith

PTA: Co-Chair

Madeline O'Donoghue

PTA: Co-Chair

Chami Gunasinghe

PTA: Secretariat

Tony
Bhalla

Revvity: Committee Member

Nicola
Brown

QIAGEN: Committee Member

Richard Harrison

MGI: Committee Member

Paul
Maguire

Siemens: Committee Member

Annie Melkonian

Cepheid: Committee Member

Alex Stephenson-Brown

Stago: Committee Member

Brad
Walsh

Minomic: Committee Member
Check back regularly as speakers are announced

Plenary Speakers

"The technology revolution - have Australians been left behind?"

Prof Patrick Tan

Executive Director, Precision Health Research, Singapore (PRECISE)
Senior Vice-Dean (Research) Duke-NUS Medical School, Chief Scientific Officer, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR). Patrick is an internationally renowned cancer researcher and pioneer for the possibilities of genomics in healthcare.

Access & Equity:  “Healthcare and the Postcode Lottery - Bridging the Gap for All Australians”

Dr Robert Grenfell

Chief Strategy & Regions Grampians Health
Rob has specialist expertise in health system analysis, strategic planning, governance, health risk management, and equity-focused care. He is passionate about access to healthcare in rural communities and bringing innovative systems to improve equity in regional settings.

Technology-driven solutions: saving lives, saving the planet, and solving problem

Dr Amandeep Hansra

Digital Health Advisor Australian Digital Health Agency & Co-Founder Australian Medical Angels
Fellow of the RACGP, Australian Digital Health Institute and Co-founder of Australian Medical Angels. Amandeep is a leader in digital health and innovation. A GP with 18 years clinical experience she is known for her work as a digital health consultant, entrepreneur, and investor.

HYPOTHETICAL SCENARIO
To invest or keep the status quo: why do we need diagnostics technology, sovereign capability and resilience?"

Co-ordinated by Sue MacLeman

 

TEAM A

Dean Whiting

Dr Gordon Reid MP

Prof Paul Griffin

Louise Talbot

Dr Amanda Cuss

Liz De Somer

Deidre Mackechnie

TEAM B

Justin Meredith

Jerome Laxale MP

Dr Robert Grenfell

Prof Rebecca Guy

Mary Warner

Dr Erin Evans

Krystal Barter

Panel Speakers

Access & Equity: "Tech-Centric Healthcare - A Cure for Our Health Crisis?"

Chair

Dr Andrew St John

Chair of IFCC Committee for Value Proposition in Laboratory Medicine
Andrew is a clinical biochemist with experience across Europe, Asia, and Australia including managing consumer information site Pathology Tests Explained. Andrew’s interests include point of care testing and how to determine economic value in medical testing.

Panellists:

Melissa McIntosh MP

Deputy Chair HoR Standing Committee on Health, Aged Care & Sport
A member of Federal Parliament since 2019, Melissa became the Shadow Assistant Minister for Mental Health and Suicide Prevention in May, 2022 and the Deputy Chair of the Hor Health Committee later the same year. She brings a voice of the Federal Opposition government and Health Committee to the panel discussion.

Prof Charlotte Hespe

Head of General Practice, Sydney School of Medicine UNDA
Specialist Clinical General Practitioner and Board Member for Central and Eastern Sydney Primary Health Network, Charlotte is passionate about improving healthcare service delivery to all Australians, and brings the voice of a GP to the panel.

Dr Robert Grenfell

Chief Strategy & Regions Grampians Health
Specialist in health system analysis, strategic planning, governance, health risk management, and equity-focused care. Rob brings the voice of a clinician and general practitioner to the panel discussion.

A/Prof Philip Cunningham

OAM, COO Medical Research St Vincent’s Centre for Applied Medical Research
Philip has decades of experience working in the field of HIV with a passion for public health surveillance of at-risk populations. Philip brings the voice of a public pathology and specialist service provider to the panel discussion.

A/Prof Fei Sim

Curtin Medical Centre & National President and Chair Pharmaceutical Society of Australia
A practising pharmacist, pharmacist immuniser, and accredited Mental Health First Aid Instructor Fei is committed to advancing the health of Australians through excellence in pharmacist practice and medicine safety through a multidisciplinary team care approach. Fei brings the voice of a pharmacist to the panel discussion.

Megan Campbell

Medical Advisor NACHHO Australia
Megan works with Aboriginal people and organisations to strengthen the cultural capability and responsiveness of the health system. Committed to evidence-informed health policy, health equity and sustainable practices, she brings the voice of a Public Health Physician to the panel discussion.

Ray Kelly

Researcher and PhD candidate, University of Melbourne
Ray is a Kamilaroi man with over 32 years’ experience in the health and sports industries, and an MRFF recipient for research into type 2 diabetes in the Aboriginal and Torres Strait Islander community. Ray brings the voice of applied research to the panel discussion.

Multi-omics and the technology revolution: “From Bench to Bedside: the winding path of Adoption of multi-omic Technology”

Professor David Thomas

Chief Executive Officer and Executive Director Omico
David has extensive training and expertise in medical oncology. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer, particularly sarcoma. David brings the voice of a clinician and researcher to the panel discussion.

Dr Jane Tiller

Ethical, Legal & Social Advisor Monash University
A lawyer, genetic counsellor, and public health researcher, Jane has a keen interest in the regulatory and ethical aspects of genomics. Currently championing for removal of insurance discrimination risk for recipients of genetic tests, Jane brings the voice of a lawyer and ethicist to the panel.

Dr Kym Mina

Director Genomics, Healius Pathology
Having worked in both public and private laboratory practice and in academia, across multiple jurisdictions in Australia and New Zealand, Kym is interested in the safe and clinically appropriate translation of genomic technologies to all fields of medical care and brings the voice of a genetic pathologist to the panel discussion.

Prof Stephen Fox

Director Pathology, Peter MacCallum Cancer Centre
Stephen has developed and implemented novel molecular cancer testing from research to diagnostic laboratories, with experience and influence in health policy and testing guidelines in AU and the UK. Peter brings the voice of a genomic specialist to the panel discussion.

Neil Everest

Senior Medical Advisor, Office of Health Technology Assessment
After spending over 10 year in paediatric medicine Neil moved into the Department of Health – starting with the TGA in premarket medicines authorisation before moving into the office of health technology assessment. Neil brings his wealth of experience in HTA processes to the panel discussion.

Enzo Ranieri

GenSCAN Deputy Chair, Principle Scientist, Head of NSW Newborn Bloodspot Screening Program
Having worked in genetic and molecular pathology research at SA Pathology identifying new biomarkers in different pathologies, Enzo leads public health screening initiatives for pre-symptomatic detection of diseases to enable early clinical intervention and targeted treatment. Enzo brings the voice of newborn screening expert to the panel discussion.

Tackling global challenges: "Shifting the paradigm: 'Pathology a cost or a vital investment?' - overcoming the barriers of new technology adoption"

A/Prof Amith Shetty

Clinical Director System Sustainability & Performance, NSW Ministry of Health
A distinguished healthcare administrator, clinician and informatician, Amith manages health service delivery, healthcare quality and safety, models of care design, value creation and evaluation through innovative approaches to healthcare delivery. Amith brings the voice of clinician strategist to the panel.

Professor Louise Cullen

Pre-Eminent Staff Specialist, Royal Brisbane and Women’s Hospital
A clinical trialist and outcomes researcher in acute diseases, Louise is involved in the translation of research by clinical redesign and innovation. She investigates methods to use medications and other resources in the ED wisely. Louise brings a voice of clinician and researcher to the panel discussion.

Dr Colman Taylor

Chief Vision Officer and Founder HTANALYSTS
Colman is a healthcare reimbursement and impact expert with a background working across government, industry and academia. Colman has over a decade of experience in healthcare innovation and brings the voice of a health economist to the panel discussion.

Professor Branwen Morgan

Minimising Antimicrobial Resistance Lead, CSIRO
A career that bridges academic organisations, publicly listed companies, government, and NGOs in the UK and Australia, across communications, project management, and Director roles. Branwen holds broad biomedical knowledge, digital understanding, and has a strong focus on AMR. Branwen brings a voice of strategist to the panel.

Martin Canova

Executive Director Strategy & Transformation, NSW Health
Martin has more than 20 years’ health experience as a clinician, healthcare consultant and health manager in both government and private organisations in Australia. He leads strategic planning and capital infrastructure redevelopment as well Statewide Point of Care Testing and Genomics services. Martin brings a voice of local government to the panel discussion.

Jo Taranto

Managing Director, Good for the Hood
Jo leads sustainable education initiatives with community, local government, and industry to inspire behaviour change towards sustainability goals. Passionate about inspiring ordinary people to create extraordinary change, Jo brings a voice of circular economy expert to the panel.

 

WORKSHOP SUBJECT MATTER EXPERTS

Access & Equity:

Solutions for all, including indigenous, rural, and hard to reach communities

A/Prof Philip Cunningham

Megan Campbell

Expanding Access to Pathology Services: Embracing Innovations in Healthcare Delivery

Prof Charlotte Hespe

A/Prof Fei Sim

Dr Andrew St John

Keeping Patients Out of the Hospital: Arresting cascading health conditions

A/Prof Amith Shetty

Dr Robert Grenfell

Ray Kelly

Multi-omics and the technology revolution:

Evolving the System: Funding and Infrastructure for the technology revolution

Dr Jane Tiller

Kym Mina

Enzo Ranieri

Up Close & Personal: deep dive into personalised care models

Prof David Thomas

Diana Nielson

Krystal Barter

Learning from Our Neighbours: where in the world is best-practice integration of multi-omics into healthcare?

Franz Pichler

Prof Stephen Fox

Tackling global challenges:

Patient-centric Technology: Putting Patients at the Heart of Innovation

Prof Louise Cullen

A/Prof Coman Taylor

Deidre Mackechnie

Addressing Global Priorities: From Defence and Antibiotic Stewardship to Green Economies

Prof Branwen Morgan

Prof Paul Griffin

Jo Taranto

Driving Efficiency: Automation and Digital Enablers

Madhuri Hegde

Adam Zembrzuski

Prof Amith Shetty

PROGRAM AT A GLANCE

TUESDAY 12th MARCH
7:30-17:30 Registration Desk Open
7:45-8:45 Industry Sponsored Breakfast
8:45-9:15 Welcome to Country and Opening Ceremony
9:15-10:15 Opening Keynote
10:15 – 10:45 Morning Tea & Industry Exhibition
10:45 – 12:30 Concurrent Symposia 1 Concurrent Symposia 2
12:30 – 13:45 Lunch & Industry Exhibition Industry Sponsored Workshop
13:45 – 15:15 Concurrent Panel Discussion 1 Industry Sponsored Roundtable
15:15 – 15:45 Afternoon Tea & Industry Exhibition
15:45 – 17:00 Afternoon Symposium
17:00 – 19:00 Welcome Cocktail Networking & Industry Exhibition Sponsored By
WEDNESDAY 13th MARCH
7:30-15:45 Registration Desk Open
7:45-8:45 Industry Sponsored Breakfast
8:45-9:30 Day 2 Keynote
7:45-8:45 Industry Sponsored Breakfast
9:30-10:45 Concurrent Symposia 3 Concurrent Symposia 4
10:45 – 11:15 Morning Tea & Industry Exhibition
11:15 – 12:45 Concurrent Panel Discussion 3 Industry Sponsored Roundtable
12:45 – 13:45 Lunch & Industry Exhibition Industry Sponsored Workshop
13:45 – 15:15 Panel Discussion and Forum
15:15 – 15:45 Afternoon Tea & Industry Exhibition
15:45 – 16:45 Afternoon Symposium
16:45 – 17:15 Closing Remarks
18:30 – 22:00 Gala Dinner Sponsored By
  • PO Box 298 Parramatta NSW 2124
2026 All rights reserved. | Website by Converge Design
Pathology Technology Australia | Contact
Click to access the login or register cheese